Xueba’s medical black technology system

Chapter 168 Science editor’s evaluation

late at night.

Across the Atlantic in Massachusetts, along the Charles River a few kilometers west of Boston, Harvard University is located.

Light spills from the windows on the fifth floor of an office building.

Professor William Kaelin, who is over sixty years old and has gray hair, is still sitting in front of the computer.

As if he heard the bells from the church in the distance, Professor William in front of the computer raised his hand and glanced at the time on his watch. It was already past nine o'clock in the evening.

As an old man, he should take a rest at this point, but Professor William put down his hand indifferently and continued to look at the manuscript in his mailbox.

He is reviewing the manuscript now.

As a scholar in the field of tumor biology and winner of the Nobel Prize in Physiology, William received an invitation from the journal Science this year to assume the editorship of Science.

Although this editorial position did not provide him with a high salary, William was still very happy.

In fact, most academic journals are edited by well-known professors or scholars in related fields, and they choose to take on such work out of obligation.

After taking up the position of editor of Science, William discovered that he had thought that the job of editing was too simple.

William originally thought that Science, as a world-renowned academic journal, would have countless people submitting articles.

As an editor, what you have to do is to do a simple screening before submitting the article for review.

Just reject the articles that are not good enough, and then select the articles that are of a certain level and send them to the reviewers for review.

Something simple and relaxing.

But William soon discovered that he was only half right.

In fact, there are indeed many people submitting articles to the official issue of Science, and William's mailbox is full every day.

But the problem is, the quality of these submitted articles is simply not good enough!

None can beat.

William admitted that this may have something to do with his high vision.

But he did not dare to lower his requirements. After all, he did not want the quality of Science's official journals to decline during his tenure as editor of Science.

This is a disgrace to his reputation.

In this case, William is now rejecting manuscripts like crazy.

"Reject it. There are more logical holes in your article than there are holes in my grandpa's vest!"

"I usually like to give suggestions to other people's articles, but this article is just a waste of my life. I refuse to accept it!"

"I can't help but admire your wild imagination. Rather than being a scientific researcher, I think you are more suitable to be a science fiction author. Reject the manuscript!"

"What we do is cutting-edge science, not archeology. Where did you dig up this kind of old antique research? Refuse to accept it!"

"Your research reminds me of Romeo and Juliet. Don't get me wrong. I'm not complimenting you. What I mean is that your research is a tragedy from beginning to end. Reject it!"

"Reject! Reject! Reject!".
William is already furious at this moment. The editor of the journal will not be polite to you if he rejects the manuscript.

Nearly [-]% of the manuscripts in the mailbox were directly passed by William without hesitation.

The remaining [-]% of the manuscripts were rejected by PASS after hesitating for a while.

After rejecting more than a dozen articles in one breath, William couldn't help but sigh.

Is there really no quality article at all?

If the current academic circle is at this level, even if it is not a pill.

Although he thought so, William still had to continue looking down.

When he saw the next submitted article, William couldn't help but narrow his eyes slightly.

"The connection between PD-1/TIGIT immune checkpoint and lung cancer and clinical research results"

PD-1 immune checkpoint?

Isn’t this research from the last century?
What an antique thing? William couldn't help but shook his head. He subconsciously glanced at the author of this article.

Liang Lu.

This kind of name is very recognizable in William's eyes. At a glance, he knows that it is a contribution from a scholar from China.

William sometimes often hears colleagues talking about scholars from China who have begun to surpass them in academic achievements.

William thinks so too, because in recent years, the number of papers published by Chinese scholars in journals with high impact factors has begun to increase in a visible way.

That's in other areas, though.

As for the field of medicine, William feels that there is still a long way to go for Chinese scholars to catch up.

For example, after he became the editor of Science, he rejected as many as [-] articles from China.

So far, he has not seen any Chinese scholar who can write an article that caught his eye.

Not a single one!

Including the article in front of him, William almost rejected it directly just by looking at the title of the article.

Because since 1992, Professor Tasukuo of Kyoto University discovered the PD-1 immune checkpoint.

A large number of scientific researchers have poured into the field of immunotherapy to conduct research, and research on PD-1 is endless.

So far, the PD-1 immune checkpoint is almost exhausted.

If it weren't for the TIGIT immune checkpoint added to the title of the article, which is a new immune checkpoint that was discovered only recently, William would be slightly more interested.

Otherwise, he would have rejected the article long ago.

However, William is still not optimistic about this article. He estimates that this article, like the previous articles, will be rejected by him after just two glances.

Thinking of this, William didn't waste any time, and took the lead in scanning the abstract of the article.

"By simultaneously inhibiting the two immune checkpoints of PD-1 and TIGIT, it exerts a synergistic inhibitory effect and upregulates the immune killing of T cells and NK cells, effectively curbing the occurrence and development of tumors and preventing immune escape."

When he saw this line of the abstract, William was stunned for a moment.Wait and suppress at the same time?

When he saw these words, William subconsciously widened his eyes,
William originally thought that this study was to individually inhibit two immune checkpoints, PD-1 and TIGIT, and then compare their immunotherapy effects on cancer cells.

After all, current research on immunotherapy inhibits a single immune checkpoint.

The other party exceeded his expectations. The other party directly inhibited the two immune checkpoints of PD-1 and TIGIT at the same time.

Most importantly, there is a synergistic effect between these two immune checkpoints.

hiss!
There is something to this idea!

William's eyes lit up.

His expression changed from contempt to surprise.

He admitted that the article had successfully piqued his curiosity.

You know, as a scholar who has been immersed in the field of oncology for many years, he has never seen any strange ideas.

In a sense, there are really not many things that interest him!

William then looked down, but soon, he showed a look of astonishment.

Because he discovered another highlight of this article.

Logically speaking, a monoclonal antibody should only inhibit one immune checkpoint.

But the other party stated in the article that he had developed a monoclonal antibody that can inhibit two immune checkpoints at the same time!

This made William's breathing suddenly become rapid.

William admitted that he had made a mistake just now!

This is definitely not some old-fashioned research. On the contrary, this research has broken through the current cutting-edge science. The cultivation method of this monoclonal antibody is amazing enough.

William couldn't wait to read on. He wanted to see how the other party cultivated this kind of monoclonal antibody.

As William turned all the way down, he was soon dumbfounded.

Therefore, he discovered that this scholar named Lu Liang directly summarized the cultivation of monoclonal antibodies into the experimental materials and briefly mentioned it.

It feels like you stop talking mid-sentence.

Isn’t this appetizing?

After coming back to his senses, this made William stamp his feet anxiously.

This is valuable research!
Just the cultivation of monoclonal antibodies could make a good article!
The other party actually took it over with just one stroke?

In William's opinion, it was simply a waste of natural resources.

William was quite depressed.

There was no way, William could only continue to look down, and he quickly saw the test results part.

However, when William saw the chart data, William's pupils suddenly shrank.

"Thick Mud Crab!"

William murmured, his eyes fixed on the screen, and even his expression became a little surprised.

At that moment, he suddenly understood why the other party ignored the cultivation of monoclonal antibodies.

The cultivation of monoclonal antibodies is certainly valuable, but in the face of this test result, that value is not worth mentioning at all.

Because the test results are the real highlight!

EGFR gene mutation ORR: 97%, ALK gene mutation ORR: 90%, ROS fusion gene ORR: 82%
This includes almost all types of mutations in lung cancer.

Not only clinical data, but also animal testing data.

This massive data result is like an indestructible foundation, firmly supporting the results and opinions of the entire article!

No matter from any angle, such an article cannot be questioned.

William's fingers trembled slightly. As a scholar of oncology, he knew what this paper meant.

After coming back to his senses, William suddenly opened his mailbox and found the email addresses of several reviewers. He needed to send this paper to the reviewers as soon as possible.

This kind of sensational research must be reviewed non-stop and published without any delay.

When sending this paper to the reviewers, William did not forget to note that it was urgent and asked the reviewers to finish the review as soon as possible.

After doing all this, William just breathed a sigh of relief. Then he stood up and made himself a cup of coffee, and then read the entire article from beginning to end.

Sufficient data, clear thinking, rigorous logic, simply perfect!
If I have to find fault, it would be that the method for cultivating monoclonal antibodies is not written down.

William is still thinking about this.

Finally, William drank the coffee in one gulp and couldn't help but smack his tongue, as if he was reminiscing.

If he were a reviewer, he would definitely have reviewed this article.

Too bad he wasn't.

However, William believes that the other three reviewers will probably make the same evaluation as him after reading this article.

After all, anyone with some skills can see the meaning of this article.

Unless that person is not good enough.

Then, his eyes fell on the position of the first author of the paper.

Liang Lu.

However, this time William's eyes no longer had the previous contempt, and he silently wrote down the name.

If there is a chance in the future, we should have a good communication, William thought to himself.

(End of this chapter)